Investor's Business Daily on MSN

Could 2026 be Dexcom's 'get right' year? New CEO Jake Leach says yes.

For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is ...
The Motley Fool

If You'd Invested $1,000 in DexCom 10 Years Ago, Here's How Much You'd Have Today

DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...
Seeking Alpha

DexCom May Be The Most Underrated Growth Story In Healthcare

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...